CereVasc Receives Approval for STRIDE Clinical Trial of the eShunt® System for the Treatment of Elderly Patients with Normal Pressure Hydrocephalus in Argentina

With approval from ANMAT, CereVasc has initiated enrollment of the STRIDE trial in Argentina BOSTON, Feb. 13, 2025 /PRNewswire/ -- CereVasc, Inc., a clinical-stage medical device company developing novel treatments for neurological diseases, announced today that it has received approval...